Nifedipine double-release controlled release tablet and preparation method thereof
The dual-release tablet design addresses initial drug release lag and production hazards by integrating rapid and controlled release technologies with stable polymer materials, ensuring immediate and long-lasting efficacy and safe production.
Patent Information
- Application Number
- CN202411565342.8
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-11-05
- Publication Date
- 2024-12-03
- Estimated Expiration
- Not applicable · inactive patent
AI Technical Summary
Existing osmotic pump controlled-release tablets for nifedipine suffer from initial drug release time lag, affecting timely clinical therapeutic effects and stability, and their production processes are complex and hazardous due to the use of organic solvents and materials prone to degradation.
A dual-release controlled-release tablet design combining rapid-release and controlled-release technologies, utilizing polymer materials with specific viscosities and stability properties, and a production method that avoids organic solvents, ensuring immediate drug release and stable long-term efficacy by coating a rapid-release layer over a controlled-release part.
The dual-release tablet achieves immediate drug efficacy followed by controlled release, stabilizing clinical effects for over 24 hours, with a smooth production process that enhances product quality and safety.
Smart Images

Figure CN119055608A_ABST
Abstract
Description
Technical Field
[0001] The present invention belongs to the field of medical technology, and is a dual-release controlled-release preparation containing active drug nifedipine and a preparation method thereof. By combining the rapid-release and controlled-release technologies, the initial drug release time lag problem of the osmotic pump controlled-release preparation is improved, and the drug is combined with immediate effect and long-term effect in clinical treatment, ensuring the long-lasting and stable full-course clinical treatment effect of the drug. The formulation of polymer materials with strong adsorption and good stability is used to improve the stability of the product release and the smoothness of the production process. Background Art
[0002] Nifedipine is a first-generation calcium ion antagonist antihypertensive drug of the dihydropyridine class. Its chemical name is 2,6-dimethyl-4 (2-nitrophenyl)-1,4-dihydro-3,5-pyridinedicarboxylic acid dimethyl ester. It is mainly used in the treatment of hypertension and angina pectoris. Common preparations of nifedipine mainly include tablets and capsules. They are absorbed and eliminated quickly after oral administration. In order to maintain clinical efficacy, it is necessary to take the medicine multiple times (3-4 times) a day, which forms a high peak-valley phenomenon in the blood drug concentration in the body. The drug effect lasts for a short time and has adverse reactions such as edema, headache, rash and constipation. Nifedipine sustained-release preparations mainly include sustained-release tablets, sustained-release capsules and controlled-release tablets. Sustained-release preparations reduce the number of medications, and the medication is taken 1-2 times a day, which reduces the peak-valley phenomenon of blood drug concentration in the body, further reduces adverse drug reactions, improves the bioavailability of the drug, and stabilizes the clinical treatment effect.
[0003] Nifedipine dual-release controlled-release tablets use double-layer push-pull osmotic pump controlled-release technology, which consists of a drug layer, a booster layer and a semi-permeable membrane. One or more drug-release holes are punched on the surface of the drug layer semi-permeable membrane. The drug release is controlled by adjusting the penetration rate of water in the semi-permeable membrane and the osmotic pressure of the drug layer and the booster layer. Nifedipine controlled-release tablets are taken once a day, which can maintain the efficacy for 24 hours, and the bioavailability is increased from 60% of ordinary preparations to 80%. The oral peak time of ordinary preparations is 30-45 minutes, and the half-life is 2-3 hours. The oral peak time of controlled-release tablets is 6 hours, and the half-life is extended to more than 8 hours, which solves the sudden release phenomenon of ordinary preparations and avoids the problem of large fluctuations in blood drug concentration. It more effectively reduces the adverse reactions of drugs and stabilizes the clinical antihypertensive treatment effect. Osmotic pump controlled-release technology is the most advanced technology for the preparation of sustained-release preparations for oral poorly soluble drugs, and it is also a hot and difficult technology in the current research of sustained-release oral solid preparations.
[0004] The nifedipine controlled-release tablets currently on the market abroad include Adalat GITS (Baixintong) developed by Bayer in Germany and Procardia XL developed by Pfizer in the United States. Domestic companies such as Shanghai Xiandai Company, Beijing Honglin Company, and Dezhou Deyao Company all have products on the market. After oral administration of osmotic pump controlled-release tablets, water dissolves the water-soluble components in the semi-permeable membrane to form pores, and then water enters the drug layer and booster layer of the double-layer tablet through the pores of the semi-permeable membrane. The swelling agent polymer materials and osmotic pressure-promoting inorganic salts in the drug layer and booster layer absorb water to increase their volume and soften. Due to the relative solidification of the semi-permeable membrane and the relative fixation of the contained volume, the drug layer is squeezed and gradually releases the drug from the drug release pores. It takes a certain amount of time for the water-soluble components in the semi-permeable membrane to dissolve and the drug layer and the swelling polymer materials in the booster layer to absorb water, resulting in the drug being released about 2 hours after oral administration. The relatively uniform drug release rate is a significant advantage of osmotic pump controlled-release preparations, but there is also a deficiency of delayed drug release in the early stage of drug release, which affects the timely treatment of patients after medication. After searching the patents of nifedipine controlled-release tablets, it was found that the patents of Beijing Honglin Pharmaceutical Co., Ltd. (CN200610113984.X), Shanghai Hualian Pharmaceutical Co., Ltd. (CN95113357.8) and Hefei Huafang Pharmaceutical Co., Ltd. (CN201110049292.4) are all push-pull osmotic pump controlled-release technologies, all of which are conventional osmotic pump prescription processes and all have the disadvantage of delayed drug release in the initial stage of drug release.
[0005] Since the drug layer and the booster layer contain swelling agent polymer materials, such polymer materials have adhesive properties. Beijing Honglin Pharmaceutical Co., Ltd. (CN200610113984.X) and Shijiazhuang Pharmaceutical Group Zhongqi Pharmaceutical Technology Co., Ltd. (CN103565769.A) use fluidized beds as granulation equipment, and use a certain concentration of organic solvent (such as ethanol) and a certain concentration of water-soluble cellulose aqueous solution or suspension as adhesives for granulation. The fluidized bed operation cycle is long, the batch size is small, and the production process is complicated. The production of organic solvents as adhesives has safety hazards. At the same time, the organic solvent residues in the product are also prone to adverse reactions. Using a certain concentration of water-soluble cellulose aqueous solution or suspension as an adhesive is prone to cause differences in particle fineness and hardness, which is easy to cause tableting quality problems and thus have an adverse effect on product quality uniformity. In the booster layer formulation, high molecular weight polyoxyethylene formulations with greater adhesiveness are often used. Since high molecular weight polyoxyethylene is easily oxidized and degraded, the stability of the product release is affected to a certain extent. Summary of the invention
[0006] The present invention belongs to the field of medical technology and is a dual-release controlled-release preparation containing the active drug nifedipine and a preparation method thereof. By combining the rapid-release and controlled-release technologies, the disadvantage of the initial drug release time lag in the prescription process of the general osmotic pump controlled-release technology is overcome, thereby ensuring the immediate and long-acting clinical therapeutic effects of the drug.
[0007] The present invention overcomes the initial drug release time lag problem of osmotic pump controlled release tablets, and coats the rapid-release drug in the outer layer of the controlled-release drug part in the form of a film coating, thereby improving the immediate effect of the drug. After oral administration of the osmotic pump controlled-release preparation, moisture enters the tablet core through the controlled-release semi-permeable membrane, and the controlled-release auxiliary materials of the drug layer and the booster layer absorb water and swell to generate a driving force for drug release. It takes a certain amount of time for moisture to penetrate into the tablet core, and generally the drug begins to be gradually released 1-2 hours after oral administration. The initial drug release time lag of the osmotic pump controlled-release preparation affects the clinical therapeutic effect of the drug. The present invention improves the time lag problem by attaching a rapid-release drug to the controlled-release drug part. After oral administration of the drug, the drug is released to produce drug efficacy, and then the controlled-release drug part is gradually released, which solves the problem of the gap in drug efficacy in the initial time period of controlled-release drug release and improves the clinical therapeutic effect.
[0008] The patent of the present invention makes full use of the characteristics of polymer materials in the formulation, coordinates materials with different viscosities, controls the preparation of particles to an appropriate degree, solves the problem of drug layer and booster layer granulation adhesion, and improves the smoothness of mass production. In the formulation design of the drug tablet core booster layer, a polymer material with strong water absorption and greater stability (such as low-substituted hydroxypropyl cellulose and polyvinyl pyrrolidone copolymer) is used for formulation, and a polymer material with good expansion but poor hygroscopicity (such as sodium carboxymethyl starch) is also used in the formulation, avoiding the product stability problem caused by the easy decomposition of high molecular weight polyethylene oxide, solving the production process problems such as the sticky web of granulation soft materials, hard particles, and tableting hard spots, and also reducing the moisture absorption of the drug to ensure the stability of the drug.
[0009] The drug release of the nifedipine dual-release controlled-release tablet of the present invention consists of a quick-release part and a controlled-release part, wherein the quick-release part is attached to the controlled-release part in the form of a coating, and the controlled-release part consists of a drug layer, a booster layer, a semi-permeable membrane, and a laser hole. The quick-release part mainly consists of a drug, a diluent, and a binder; the drug layer of the controlled-release part consists of a drug, a carrier swelling agent, an osmotic pressure promoter, a lubricating glidant, etc.; the booster layer of the controlled-release part consists of a carrier swelling agent, an osmotic pressure promoter, a lubricating glidant, etc.; the semi-permeable membrane of the controlled-release part mainly consists of water-insoluble cellulose, a plasticizer, and a pore-forming agent, etc.; the film coating mainly consists of water-soluble cellulose, a curing agent, a plasticizer, and a light-shielding colorant, etc. The composition of each part of the drug has the following proportion range: the quick-release part accounts for 10-20%, the drug layer of the controlled-release part accounts for 40-70%, the booster layer of the controlled-release part accounts for 20-50%, the semi-permeable membrane of the controlled-release part accounts for 10-20%, and the film coating accounts for 2-5%.
[0010] Furthermore, the immediate-release portion of the nifedipine dual-release controlled-release tablets is mainly composed of drugs, diluents and binders, of which the drugs account for 10-20%, the diluents account for 40-80%, and the binders account for 10-20%. The diluents are mainly composed of starch, compressible starch, lactose, sucrose, dextrin, talc, titanium dioxide and other materials, and the binders are mainly composed of hydroxypropyl methylcellulose, methylcellulose, hydroxypropyl cellulose, povidone, polyvinyl pyrrolidone copolymer and other materials.
[0011] Furthermore, the controlled release drug layer of the nifedipine dual-release controlled-release tablets is composed of drugs, carrier expanders, osmotic pressure enhancers, lubricating glidants, etc., of which the drugs account for 10-30%, the carrier expanders account for 60-90%, the osmotic pressure enhancers account for 20-40%, and the lubricating glidants account for 2-10%. The carrier expanders mainly include polyoxyethylene, polyvinyl pyrrolidone copolymer, carbomer, hydroxypropyl methylcellulose, etc., the osmotic pressure enhancers mainly include sodium chloride, potassium chloride, magnesium chloride, potassium sulfate and sodium sulfate, etc., and the lubricating glidants mainly include magnesium stearate, talc, silicon dioxide, etc.
[0012] The booster layer of the controlled release part of the nifedipine dual-release controlled release tablet of the present invention is composed of a carrier swelling agent, an osmotic pressure promoter, a lubricating glidant, etc., wherein the carrier swelling agent accounts for 60-90%, the osmotic pressure promoter accounts for 20-40%, and the lubricating glidant accounts for 2-10%. The carrier swelling agent mainly includes polyvinylpyrrolidone copolymer, carbomer, hydroxypropyl methylcellulose, low-substituted hydroxypropyl methylcellulose, sodium carboxymethyl starch and cross-linked sodium carboxymethyl cellulose, the osmotic pressure promoter mainly includes sodium chloride, potassium chloride, magnesium chloride, potassium sulfate and sodium sulfate, and the lubricating glidant mainly includes magnesium stearate, talc, silicon dioxide, etc.
[0013] The semi-permeable membrane of the controlled release part of the nifedipine dual-release controlled release tablet of the present invention is mainly composed of water-insoluble cellulose, a plasticizer and a pore-forming agent, wherein the water-insoluble cellulose accounts for 60-90%, the plasticizer accounts for 10-20%, and the pore-forming agent accounts for 10-20%. The water-insoluble cellulose mainly includes cellulose acetate, ethyl cellulose, etc., the plasticizer mainly includes propylene glycol, diethyl phthalate, triethyl citrate, etc., and the pore-forming agent mainly includes polyethylene glycols of various molecular weights.
[0014] The film coating of the nifedipine dual-release controlled-release tablet of the present invention mainly consists of water-soluble cellulose, a curing agent, a plasticizer, a light-shielding colorant, etc., wherein the water-soluble cellulose accounts for 40-80%, the curing agent accounts for 20-50%, the plasticizer accounts for 2-10%, and the light-shielding colorant accounts for 2-10%. The water-soluble cellulose mainly includes hydroxypropyl methylcellulose, hydroxypropyl cellulose, methyl cellulose, sodium carboxymethyl cellulose, etc., the curing agent mainly includes talc, titanium dioxide, silicon dioxide, magnesium stearate, calcium sulfate, etc., the plasticizer mainly includes glycerol, propylene glycol, polyethylene glycol, etc., and the light-shielding colorant mainly includes red iron oxide, brown iron oxide, amaranth, apple green, etc.
[0015] The present invention also aims to provide a method for preparing a nifedipine dual-release controlled-release tablet, which makes full use of the viscosity characteristics of the polymer materials of the drug layer and the booster layer by improving the production equipment and facilities, and directly prepares suitable particles by adding water as a binder in an atomized form under stirring conditions. The method is simple and environmentally friendly to produce, the production process is smooth, the product quality is stable, the use of organic solvents in the granulation link and the residual organic solvents in the product are avoided, and the safety of the clinical application of the product is further improved. In the granulation process, conventional high-speed wet granulation or fluidized bed granulation is used to smoothly obtain particles that are easy to tablet in large-scale production. The tablet is mass-produced, the tablet surface is smooth, the hardness is moderate, and it is suitable for the next step of semi-permeable membrane coating production. The controlled-release semi-permeable membrane coating is produced by a high-efficiency coating machine, the high-efficiency coating machine is subjected to air inlet temperature and humidity control and organic solvent recovery modification, and the spray gun device is also modified to ensure the uniformity between tablets and batches of the coating film.
[0016] The preparation method of the controlled release part of the nifedipine dual-release controlled release tablet of the present invention is that the drug layer and the booster layer of the controlled release part are prepared into particles in the form of atomization using water as a binder, the drug layer and the booster layer particles are pressed into a double-layer tablet, and then a semi-permeable membrane is coated on the outer layer of the double-layer tablet, and a small hole is made on the semi-permeable membrane surface of the drug layer by laser. The preparation method of the immediate release part is that the immediate release component is prepared into a suspension using water as a solvent, and the suspension is coated on the outer layer of the controlled release part in the form of a coating. The film coating component is prepared into a suspension using water as a solvent, and the suspension is coated on the outer layer of the immediate release part in the form of a coating.
[0017] The preparation method of the quick-release part of the nifedipine dual-release controlled-release tablet of the present invention is to mix the drug layer, diluent and binder evenly, add a certain amount of water to the mixed raw and auxiliary materials, stir appropriately to prepare a suspension, and evenly spray and coat the outer layer of the controlled-release part in the form of spray coating.
[0018] The preparation method of the controlled release part drug layer particles of the nifedipine dual-release controlled release tablet of the present invention is to mix the drug, carrier swelling agent and osmotic pressure enhancer evenly, use water as a binder to granulate in an atomized form using a fluidized bed or wet granulator, add a lubricating glidant after the particles are dried, and mix evenly to prepare drug layer particles for tableting.
[0019] The preparation of the booster layer particles of the controlled release part of the nifedipine dual-release controlled release tablet of the present invention mainly comprises the following steps: uniformly mixing a carrier swelling agent and an osmotic pressure enhancer, using water as a binder to granulate in an atomized form using a fluidized bed or wet granulator, adding a lubricating glidant after the particles are dried, and uniformly mixing to prepare the booster layer particles for tableting.
[0020] The semi-permeable membrane part of the nifedipine dual-release controlled-release tablet of the present invention is prepared by using one or more solvents such as acetone, ethanol, isopropanol, etc. as solvents to dissolve the components of the semi-permeable membrane part to prepare a uniformly dissolved semi-permeable membrane coating solution, which is evenly sprayed and coated on the outer surface of the controlled-release part in a coating machine.
[0021] The film coating part of the nifedipine dual-release controlled-release tablet of the present invention is prepared by dissolving the film coating components with water to prepare a uniformly dissolved or suspended film coating liquid, which is uniformly sprayed and coated on the outer layer of the quick-release part in a coating machine.
[0022] The nifedipine dual-release controlled-release tablets prepared according to the present invention were subjected to accelerated testing in a constant temperature and humidity chamber at 40±2°C and a relative humidity of 75%±5% for 6 months and stored at 25±2°C and a relative humidity of 75%±5% for 2 years. The appearance, properties, related substances, solubility and content of the nifedipine dual-release controlled-release tablets showed no significant changes compared with those at 0 months. It can be inferred that the nifedipine controlled-release tablets according to the present invention can make the preparation effective for more than 2 years. BRIEF DESCRIPTION OF THE DRAWINGS
[0023] Figure 1 It is a dissolution curve diagram of the nifedipine dual-release controlled-release tablets of the present invention.
[0024] Figure 2 It is a dissolution curve diagram of the nifedipine dual-release controlled-release tablets according to Example 1 of the present invention.
[0025] Figure 3 It is a dissolution curve diagram of nifedipine dual-release controlled-release tablets according to Example 2 of the present invention. DETAILED DESCRIPTION
[0026] The present invention will be further described below by specific embodiments. Those skilled in the art should understand that these descriptions are not intended to limit the protection scope of the present invention, and equivalent replacements or corresponding improvements made based on the records in the embodiments still fall within the protection scope of the present invention.
[0027] Example 1. Preparation of nifedipine dual-release controlled-release tablets (1) Preparation of double-layer tablet core ①Drug layer Nifedipine 30 g Polyoxyethylene 90 g Hydroxypropyl methylcellulose 10 g Sodium chloride 10 g Silicon dioxide 1 g Magnesium stearate 1 g The above-prescribed amounts of nifedipine, polyoxyethylene, hydroxypropyl methylcellulose and sodium chloride are mixed uniformly in a high-speed wet granulator, and water is used as a binder and added to the high-speed wet granulator in an atomized form for granulation. The obtained granules are dried under ventilation at 50° C., and then silicon dioxide and magnesium stearate are added and mixed uniformly for use.
[0028] ②Boosting layer Cross-linked carboxymethyl cellulose sodium 50 g Sodium carboxymethyl starch 10 g Sodium chloride 15 g Red iron oxide 2 g Silicon dioxide 0.5 g Magnesium stearate 0.5 g The cross-linked sodium carboxymethyl cellulose, sodium carboxymethyl starch, sodium chloride and red iron oxide in the above prescription amounts are mixed evenly in a high-speed wet granulator, and water is used as a binder in an atomized form and added to the high-speed wet granulator for granulation. The obtained granules are dried under ventilation at 50° C., and then silicon dioxide and magnesium stearate are added and mixed evenly for use.
[0029] ③ Tablet pressing Drug layer particles 71% Boosting layer particles 29% Using a double-layer tablet press, tablets weighing about 220 mg were pressed using 8 mm diameter shallow concave punches. The tablet weight and hardness were tested during the tableting process.
[0030] (2) Preparation of controlled release semi-permeable membrane coating Cellulose acetate 6 g Diethyl phthalate 1 g Polyethylene glycol 1000 1 g Acetone 1000 ml Use acetone as solvent, add the above-prescribed auxiliary materials of cellulose acetate, diethyl phthalate and polyethylene glycol 1000, stir evenly to prepare a semi-permeable membrane coating liquid, use a high-efficiency coating machine to coat the double-layer tablets prepared by the above process with a controlled-release semi-permeable membrane, the tablet bed temperature is 10-20°C, and the coating weight gain is 8-15%.
[0031] A total of 1000 tablets were produced.
[0032] (3) Laser drilling A laser puncher was used to punch holes on the surface of the drug layer, with a hole diameter of 0.8 mm.
[0033] (4) Rapid-release film coating Nifedipine 3 g Lactose 5 g Talc 10 g Hydroxypropyl methylcellulose 4 g 200ml water Add the prescribed amount of nifedipine, lactose, talcum powder and hydroxypropyl methylcellulose into 200 ml of water, stir and disperse evenly to prepare a drug layer coating suspension, coat the immediate-release drug layer on the outer layer of the controlled-release tablet according to the film coating process, and attach the immediate-release drug layer to the outer layer of the controlled-release tablet.
[0034] (5) Preparation of gastric soluble film coating The tablets prepared by the above process were coated with a gastric soluble film using a high-efficiency coating machine, and the coating weight gain was 2%.
[0035] (6) The obtained tablets are packaged in PVC aluminum foil.
[0036] Example 2. Preparation of nifedipine dual-release controlled-release tablets (1) Preparation of double-layer tablet core ①Drug layer Nifedipine 30 g Polyvinyl pyrrolidone copolymer 100g Hydroxypropyl methylcellulose 5 g Sodium chloride 15 g Silicon dioxide 1 g Magnesium stearate 1 g The above-prescribed amounts of nifedipine, polyvinyl pyrrolidone copolymer, hydroxypropyl methylcellulose and sodium chloride are mixed uniformly in a high-speed wet granulator, and water is used as a binder and added to the high-speed wet granulator in an atomized form for granulation. The obtained granules are dried under ventilation at 50° C., and then silicon dioxide and magnesium stearate are added and mixed uniformly for use.
[0037] ②Boosting layer Low substituted hydroxypropyl methylcellulose 40 g Sodium carboxymethyl starch 20 g Sodium chloride 10 g Red iron oxide 2 g Silicon dioxide 0.5 g Magnesium stearate 0.5 g The low-substituted hydroxypropyl methylcellulose, sodium carboxymethyl starch, sodium chloride and red iron oxide in the above prescription amounts are mixed evenly in a high-speed wet granulator, and water is used as a binder and added to the high-speed wet granulator in an atomized form for granulation. The obtained granules are dried under ventilation at 50° C., and then silicon dioxide and magnesium stearate are added and mixed evenly for use.
[0038] ③ Tablet pressing Drug layer particles 68% Boosting layer particles 32% Using a double-layer tablet press, tablets weighing about 225 mg were pressed using 8 mm diameter shallow concave punches. The tablet weight and hardness were tested during the tableting process.
[0039] (2) Preparation of controlled release semi-permeable membrane coating Cellulose acetate 8 g Triethyl citrate 1.5 g Macrogol 400 1.5 g Acetone 1000 ml Take acetone as solvent, add the auxiliary materials of cellulose acetate, triethyl citrate and polyethylene glycol 400 in the above prescription amount, stir evenly to prepare a semi-permeable membrane coating liquid, use a high-efficiency coating machine to coat the double-layer tablets prepared by the above process with a controlled-release semi-permeable membrane, the tablet bed temperature is 10-20°C, and the coating weight gain is 8-15%.
[0040] A total of 1000 pieces were produced (3) Laser drilling A laser puncher was used to punch holes on the surface of the drug layer, with a hole diameter of 0.8 mm.
[0041] (4) Rapid-release film coating Nifedipine 3 g Sucrose 6 g Titanium dioxide 8 g Hydroxypropyl methylcellulose 5 g 200ml water Add the prescribed amount of nifedipine, sucrose, titanium dioxide and hydroxypropyl methylcellulose into 200 ml of water, stir and disperse evenly to prepare a drug layer coating suspension, coat the immediate-release drug layer on the outer layer of the controlled-release tablet according to the film coating process, and attach the immediate-release drug layer to the outer layer of the controlled-release tablet.
[0042] (5) Preparation of gastric soluble film coating The tablets prepared by the above process were coated with a gastric soluble film using a high-efficiency coating machine, and the coating weight gain was 2%.
[0043] (6) The obtained tablets are packaged in PVC aluminum foil.
[0044] Example Sample Testing Example 1 Sample testing and quality stability analysis The dissolution was carried out according to the dissolution and release test method (Method 2, Part 4, General Rules 0931, Chinese Pharmacopoeia 2020 Edition), and the operation was carried out in a dark place.
[0045] Dissolution conditions: Place the product in a sinker and use 900 ml of 0.5% sodium dodecyl sulfate phosphate-citrate buffer (citrate buffer: take 33.2 g disodium hydrogen phosphate dodecahydrate, 2.9 g citric acid, dissolve and dilute to 6 L with water, and adjust the pH to 6.8 with phosphoric acid) as the dissolution medium. The speed is 100 revolutions per minute. Operate according to the method. Take 10 ml of the dissolution solution at 4 hours, 8 hours, 12 hours, 16 hours and 24 hours respectively, and immediately replenish the dissolution medium with the same temperature and volume.
[0046] Take the dissolution solution of the test sample at 4 hours, 8 hours, 12 hours, 16 hours and 24 hours, filter, and accurately measure the appropriate amount of the filtrate. Test each dissolution sampling point according to the high performance liquid chromatography method, and calculate the dissolution amount of each tablet at different time points. The dissolution amount at 4 hours, 12 hours and 24 hours should be 10% to 30%, 40% to 65% and more than 85% of the labeled amount, respectively, and should comply with the regulations; within 4 to 8 hours, 8 to 12 hours and 12 to 16 hours, the average dissolution rate per hour should be 3% to 6% of the labeled amount, and should comply with the regulations.
[0047] The dissolution test results of Example 1 are shown in the following table: Example 1 Sample dissolution test results table
[0048] Example 2 Sample dissolution test The dissolution of the sample in Example 2 was tested according to the dissolution test method of the sample in Example 1. The dissolution test results of the sample in Example 2 are as follows: Example 2 Sample dissolution test results table
[0049] Accelerated tests and long-term tests were conducted according to the commercial packaging, and the results showed that under the packaging conditions, the various indicators of the product did not change significantly, and the requirements for storage and transportation conditions of the drug could be met. The nifedipine dual-release controlled-release tablets and the preparation method thereof of the present invention have stable product quality, low impurity content, simple formulation, smooth process, and also ensure product quality and clinical treatment effect, and can achieve significant social and economic benefits.
Claims
1. A nifedipine dual-release controlled-release tablet, characterized in that: The drug release consists of a rapid-release part and a controlled-release part. The rapid-release part is attached to the controlled-release part in the form of a coating, and the controlled-release part consists of a drug layer, a booster layer, a semi-permeable membrane and a laser hole; the rapid-release part mainly consists of drugs, diluents and binders; the drug layer of the controlled-release part consists of drugs, carrier expanders, osmotic pressure enhancers and lubricating glidants; the booster layer of the controlled-release part consists of carrier expanders, osmotic pressure enhancers and lubricating glidants; the semi-permeable membrane of the controlled-release part mainly consists of water-insoluble cellulose, plasticizers and pore-forming agents; the film coating mainly consists of water-soluble cellulose, a curing agent, a plasticizer and a light-shielding colorant; the composition of each part of the drug has the following proportion range: the rapid-release part accounts for 10-20%, the drug layer of the controlled-release part accounts for 40-70%, the booster layer of the controlled-release part accounts for 20-50%, the semi-permeable membrane of the controlled-release part accounts for 10-20%, and the film coating accounts for 2-5%.
2. The nifedipine dual-release controlled-release tablet according to claim 1, characterized in that: The immediate-release part is mainly composed of drugs, diluents and binders, of which the drugs account for 10-20%, the diluents account for 40-80%, and the binders account for 10-20%. The diluents are mainly composed of starch, compressible starch, lactose, sucrose, dextrin, talc, and titanium dioxide materials. The binders are mainly composed of hydroxypropyl methylcellulose, methylcellulose, hydroxypropyl cellulose, povidone, and polyvinyl pyrrolidone copolymer materials.
3. The nifedipine dual-release controlled-release tablet according to claim 1, characterized in that: The drug layer of the controlled release part is composed of drugs, carrier swelling agents, osmotic pressure enhancers, and lubricating glidants, of which drugs account for 10-30%, carrier swelling agents account for 60-90%, osmotic pressure enhancers account for 20-40%, and lubricating glidants account for 2-10%. Carrier swelling agents mainly include polyoxyethylene, polyvinyl pyrrolidone copolymer, carbomer, and hydroxypropyl methylcellulose. Osmotic pressure enhancers mainly include sodium chloride, potassium chloride, magnesium chloride, potassium sulfate, and sodium sulfate. Lubricating glidants mainly include magnesium stearate, talc, and silicon dioxide.
4. The nifedipine dual-release controlled-release tablet according to claim 1, characterized in that: The booster layer of the controlled release part is composed of a carrier expander, an osmotic pressure enhancer, and a lubricating glidant, wherein the carrier expander accounts for 60-90%, the osmotic pressure enhancer accounts for 20-40%, and the lubricating glidant accounts for 2-10%. The carrier expander mainly includes polyvinylpyrrolidone copolymer, carbomer, hydroxypropyl methylcellulose, low-substituted hydroxypropyl methylcellulose, sodium carboxymethyl starch and cross-linked sodium carboxymethyl cellulose. The osmotic pressure enhancers mainly include sodium chloride, potassium chloride, magnesium chloride, potassium sulfate and sodium sulfate. The lubricating glidant mainly includes magnesium stearate, talc and silicon dioxide.
5. The nifedipine dual-release controlled-release tablet according to claim 1, characterized in that: The semi-permeable membrane of the controlled release part is mainly composed of water-insoluble cellulose, plasticizer and pore-forming agent, among which water-insoluble cellulose accounts for 60-90%, plasticizer accounts for 10-20% and pore-forming agent accounts for 10-20%. The water-insoluble cellulose mainly includes cellulose acetate and ethyl cellulose, the plasticizer mainly includes propylene glycol, diethyl phthalate and triethyl citrate, and the pore-forming agent mainly includes polyethylene glycol of various molecular weights.
6. The nifedipine dual-release controlled-release tablet according to claim 1, characterized in that: The film coating is mainly composed of water-soluble cellulose, curing agent, plasticizer and sunshade colorant, of which water-soluble cellulose accounts for 40-80%, curing agent accounts for 20-50%, plasticizer accounts for 2-10%, and sunshade colorant accounts for 2-10%. The water-soluble cellulose mainly includes hydroxypropyl methylcellulose, hydroxypropyl cellulose, methyl cellulose, and sodium carboxymethyl cellulose. The curing agent mainly includes talc, titanium dioxide, silicon dioxide, magnesium stearate, and calcium sulfate. The plasticizer mainly includes glycerin, propylene glycol, and polyethylene glycol. The sunshade colorant mainly includes red iron oxide, brown iron oxide, amaranth red, and apple green.
7. A method for preparing the nifedipine dual-release controlled-release tablet according to any one of claims 1 to 6, characterized in that: The preparation method of the controlled release part is as follows: the drug layer and the booster layer of the controlled release part are prepared into particles in the form of atomization using water as a binder respectively, the drug layer and the booster layer particles are pressed into a double-layer tablet, and then a semi-permeable membrane is coated on the outer layer of the double-layer tablet, and a small hole is punched on the semi-permeable membrane surface of the drug layer by laser; the preparation method of the rapid release part is as follows: the rapid release component is prepared into a suspension using water as a solvent, and is coated on the outer layer of the controlled release part in the form of a coating; the film coating component is prepared into a suspension using water as a solvent, and is coated on the outer layer of the rapid release part in the form of a coating.
8. The method for preparing a nifedipine dual-release controlled-release tablet according to claim 7, characterized in that: The preparation of the immediate release part is to mix the drug layer, diluent and binder evenly, add a certain amount of water to the mixed raw and auxiliary materials, stir appropriately to prepare a suspension, and evenly spray it on the outer layer of the controlled release part in the form of spray coating.
9. The method for preparing a nifedipine dual-release controlled-release tablet according to claim 7, characterized in that: The preparation of the controlled release drug layer granules is to mix the drug, carrier swelling agent and osmotic pressure enhancer evenly, use water as a binder to granulate in the form of atomization using a fluidized bed or wet granulator, add a lubricating glidant after the granules are dried, and mix evenly to prepare the drug layer granules for tableting.
10. The method for preparing a nifedipine dual-release controlled-release tablet according to claim 7, characterized in that: The preparation of the controlled release part booster layer granules is to mix the carrier expansion agent and the osmotic pressure enhancer evenly, use water as a binder to granulate in the form of atomization using a fluidized bed or wet granulator, add a lubricating flow aid after the granules are dried, and mix evenly to prepare the booster layer granules for tableting.
11. The method for preparing a nifedipine dual-release controlled-release tablet according to claim 7, characterized in that: The preparation of the semi-permeable membrane part mainly uses one or more organic solvents such as acetone, ethanol, and isopropanol as solvents to dissolve the components of the semi-permeable membrane part to prepare a uniformly dissolved semi-permeable membrane coating solution, which is evenly sprayed and coated on the outer surface of the controlled release part in a coating machine.
12. The method for preparing a nifedipine dual-release controlled-release tablet according to claim 7, characterized in that: The film coating part is prepared by dissolving the film coating components with water to prepare a uniformly dissolved or suspended film coating liquid, which is evenly sprayed and coated on the outer layer of the quick-release part in a coating machine.
Citation Information
Patent Citations
Isosorbide mononitrate double-rate osmotic pump type controlled-release preparation and preparation method thereof
CN101642444A
Nifedipine osmotic pump controlled release tablet and preparation method thereof
CN102138912A
Nifedipine controlled release composition and preparation method thereof
CN103565769A
Nifedipine controlled release tablet and preparation method thereof
CN114681422A
Ketorolac tromethamine biphasic controlled release tablet and preparation method thereof
CN116115581A
